Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evolution of echocardiography in subclinical detection of cancer therapy–related cardiac dysfunction

Evolution of echocardiography in subclinical detection of cancer therapy–related cardiac dysfunction Cancer therapies have resulted in increased survivorship in oncological patients. However, the benefits have been marred by the development of premature cardiovascular disease. The current definition outlines measurement of ejection fraction as a mean to diagnose cancer therapeutic–related cardiac dysfunction (CTRCD); however, up to 58% of the patients do not regain their cardiac function after the CTRCD diagnosis, despite therapeutic interventions. Therefore, there has been a growing interest in the markers for early myocardial changes (ie, changes with normal left ventricular ejection fraction [LVEF]) that may predict the development of subsequent left ventricular ejection fraction reduction or progression to heart failure. This review will highlight the use of diastolic parameters, tissue Doppler imaging (TDI), and speckle tracking echocardiogram (STE) as emerging technologies which can potentially detect cardiac dysfunction thereby stratifying patients for cardioprotective therapies. The goal of this manuscript was to highlight the concepts and discuss the current controversies surrounding these echocardiographic imaging modalities. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Echocardiography Wiley

Evolution of echocardiography in subclinical detection of cancer therapy–related cardiac dysfunction

Loading next page...
 
/lp/wiley/evolution-of-echocardiography-in-subclinical-detection-of-cancer-b7uVpj2TYq

References (69)

Publisher
Wiley
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0742-2822
eISSN
1540-8175
DOI
10.1111/echo.14012
pmid
29749652
Publisher site
See Article on Publisher Site

Abstract

Cancer therapies have resulted in increased survivorship in oncological patients. However, the benefits have been marred by the development of premature cardiovascular disease. The current definition outlines measurement of ejection fraction as a mean to diagnose cancer therapeutic–related cardiac dysfunction (CTRCD); however, up to 58% of the patients do not regain their cardiac function after the CTRCD diagnosis, despite therapeutic interventions. Therefore, there has been a growing interest in the markers for early myocardial changes (ie, changes with normal left ventricular ejection fraction [LVEF]) that may predict the development of subsequent left ventricular ejection fraction reduction or progression to heart failure. This review will highlight the use of diastolic parameters, tissue Doppler imaging (TDI), and speckle tracking echocardiogram (STE) as emerging technologies which can potentially detect cardiac dysfunction thereby stratifying patients for cardioprotective therapies. The goal of this manuscript was to highlight the concepts and discuss the current controversies surrounding these echocardiographic imaging modalities.

Journal

EchocardiographyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

There are no references for this article.